Mandar Sanas
@Mandarsanas20
Post-@EHA_Hematology 2025: Most viewed women oncologists on X. #EHA2025 #EHA25 #Hematology #Cancer #Oncology #MedTwitter #LARVOL
Top Women Oncologists from @EHA_Hematology 2025. Explore the latest updates from #EHA2025: t.ly/6uoHY #LARVOL #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | @calliecoombsmd | @sghmd | @beatalleukemia | @beth_psaila | @DrPinkalDesai |…
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Learn more about TALAPRO-2 trial 👉 clin.larvol.com/trial-detail/N… #LARVOL…
Explore and plan #ESMO25 schedule better with LARVOL #Conferences #Planners #CancerResearch #ClinicalTrials #esmo25 #AIData @brunolarvol @sweta_agrw @5Reena_thakur @Davdwlkerson @Krishnaveni_Y
@myESMO Congress 2025: Titles and Abstracts Publication Schedule Announced! Stay updated on oncology conferences, top trials, and oncologist reactions with @Larvol CLIN: clin.larvol.com #LARVOL #ESMO25 #Oncology #CancerResearch #CancerData #OncologyInsights |…
🧠💊 AI is transforming cancer care: 🔍 Early detection 🧬 Precision treatment 💉 Smarter immunotherapy 💊 Faster drug discovery 📈 Predicting relapse LARVOL AI is doing exactly this to fight the deadliest cancers. #AI #Onco @Larvol @brunolarvol 🔬 Stay tuned for new updates.
We benchmarked 10 AI models for identifying biosimilar originators, with GPT-4o achieving the highest F1 score of 94%, indicating superior precision-recall balance.
We benchmarked 10 AI models on their ability to identify Originators for Biosimilars. The gap in results was massive. GPT-4o was the clear winner with a 94% F1 score, delivering the best balance of precision and recall. The key insight: Some models achieved 100% precision but…
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer globenewswire.com/news-release/2… Learn more about KEYNOTE-A78 (NCT03978689) 👉…
🎙️ New Podcast Collaboration: @ASCO 2025 Summary Judith Perez (@Jud_Prz) from @Larvol joins @VuMedi to share key takeaways from ASCO® 2025, focusing on BCMA-targeted therapies in relapsed/refractory multiple myeloma (R/R MM). #LARVOL #VuMedi #ASCO25 #CancerResearch #Oncology…
ADCs with R-GemOX in Diffuse Large B-Cell Lymphoma @EHA_Hematology 2025. #EHA2025 #EHA25 #ADC #AntibodyDrugConjugates #Immunotherapy #polatuzumab #Polivy #zilovertamab #POLARGO #WAVELINE003 #Oncology #Hematology #Lymphoma #DLBCL #lymsm #MedTwitter #CancerResearch #LARVOL
@EHA_Hematology 2025: Comparative Landscape of ADCs in Combination with R-GemOX for 2L+ R/R DLBCL. Explore the latest updates from #EHA2025: t.ly/6uoHY #LARVOL #ADCs #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | @GuiperiniMD | @dgermain21 |…
@EHA_Hematology 2025: DVRd vs VRd Outcomes in CEPHEUS and PERSEUS Trials Follow us for the latest #EHA2025 updates: t.ly/6uoHY #LARVOL #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | @Rfonsi1 | @RahulBanerjeeMD | @HadidiSamer | @bdermanmd |…
Post-@EHA_Hematology 2025: Reactions on Top Trials. #EHA2025 #EHA25 #Hematology #Cancer #Oncology #leusm #lymsm #mdssm #mmsm #mpnsm #MedTwitter #LARVOL
Reactions on top trials during @EHA_Hematology 2025 curated by @Larvol CLIN. Explore the latest updates from #EHA2025: t.ly/6uoHY #LARVOL #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | @AlkaliDr | @A_Bobin_ | @awechalekar | @calliecoombsmd |…
Attending @DrugInfoAssn 2025? Connect with Bruno Larvol (@brunolarvol), CEO, in Washington, DC. #LARVOL #DIA2025 #DIAglobal #Oncology #CancerResearch #CancerData #OncologyInsights
Subcutaneous Isatuximab studies in multiple myeloma from @EHA_Hematology 2025. Follow us for the latest #EHA2025 updates: t.ly/6uoHY #LARVOL #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | @Abdallah81MD | @HadidiSamer | @mtmdphd |…
Here's a look at Myelodysplastic syndrome (MDS) trials being presented at @EHA_Hematology 2025. Follow us for the latest #EHA2025 updates: t.ly/6uoHY #LARVOL #MDS #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | @Dr_AmerZeidan | @TalhaBadarMD |…
@EHA_Hematology 2025: Here are the highlights from day 2. Follow us for the latest #EHA2025 updates: t.ly/6uoHY #LARVOL #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | @brunolarvol
Leaving #EHA2025. Loved it. But longing for some coool air. Or even rain
@EHA_Hematology 2025 Day 4 Preview: Top Trials to Follow Here's the most anticipated hematology data, curated from the most discussed trials on X. Follow us for the latest #EHA2025 updates: t.ly/6uoHY #LARVOL #Hematology #CancerResearch #Oncology #CancerData…
Data on Sarclisa-based treatments in transplant-eligible and transplant-ineligible newly diagnosed multiple myeloma at @EHA_Hematology 2025. Follow us for the latest #EHA2025 updates: t.ly/6uoHY #LARVOL #Hematology #CancerResearch #Oncology #CancerData…
A look at FLT3 inhibitors: Quizartinib vs BMF-500 – their mechanisms, companies, and trials at @EHA_Hematology 2025. Follow us for the latest #EHA2025 updates: t.ly/6uoHY #LARVOL #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | @Dr_AmerZeidan |…
Here’s a look at studies covering CD20xCD3 T-Cell Engagers and 2L+ studies in Follicular Lymphoma from @EHA_Hematology 2025. Follow us for the latest #EHA2025 updates: t.ly/6uoHY #LARVOL #FollicularLymphoma #Hematology #CancerResearch #Oncology #CancerData…
Flying from Milan (#EHA2025) to Paris. My seat might be the most popular one these days ? What do you think ?